AFT Pharmaceuticals - Growth underpinned by international momentum
AFT Pharmaceuticals’ FY24 results demonstrated record earnings and sales, with 24.8% year-on-year sales growth. Revenues of NZ$195.4m were driven by strong domestic market performance (+13.6%) and solid traction from international (Asia and RoW) markets (+ 108% y-o-y, supported by a NZ$6m milestone payment from US partner Hikma). Investments in future growth (R&D and marketing) and sales-mix effects slightly affected margins adversely (operating margin of 12.4% in FY24 vs our expectation of 12.8%) but we anticipate the upfront investments will provide a revenue uptick from FY26. AFT’s balance sheet remains strong, allowing for a dividend announcement for FY24 (1.6c/share; c 10% payout ratio) and a reduction in debt, both positive signs for investors. We tweak our estimates for the results and FY25 guidance (operating profit of NZ$22–25m, excluding any licence payments), resulting in our valuation adjusting to NZ$725.5m or NZ$6.92/share (from NZ$698m or NZ$6.65/share).AFT Pharmaceuticals is engaged in the distribution of pharmaceutical products and the development of pharmaceutical intellectual property.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.